Diurnal Group PLC Director Dealings (4454Y)
May 12 2021 - 11:32AM
UK Regulatory
TIDMDNL
RNS Number : 4454Y
Diurnal Group PLC
12 May 2021
12 May 2021
Diurnal Group plc
("Diurnal" or the "Company")
Director Dealings
Diurnal Group plc (AIM: DNL), the specialty pharmaceutical
company targeting patient needs in chronic endocrine (hormonal)
diseases, announces the following Directors' dealings undertaken
for tax planning purposes:
Richard Ross, Chief Scientific Officer sold 22,000 Ordinary
Shares and his wife (Sarah Ross) sold 20,000 Ordinary Shares at a
price of 66.5 pence per Ordinary Share; his and his wife's ISAs
purchased 22,000 Ordinary Shares and 20,000 Ordinary Shares
respectively at a price of 66.55 pence per Ordinary Share.
Following the transactions, the total beneficial interest of
Richard Ross and his connected parties remains unchanged at
2,221,093 Ordinary Shares, representing 1.3% of the total voting
rights as at 12 May 2021.
Details of the full notifications received by the Company are
set out below:
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Richard Ross
----------------------------- ---------------------------------------------
2 Reason for the notification
----------------------------------------------------------------------------
a) Position/status Chief Scientific Officer
----------------------------- ---------------------------------------------
b) Initial notification Initial notification
/Amendment
----------------------------- ---------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
----------------------------------------------------------------------------
a) Name Diurnal Group plc
----------------------------- ---------------------------------------------
b) LEI 213800I2HNUNZN1LDH29
----------------------------- ---------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
----------------------------------------------------------------------------
a) Description of the Ordinary shares of 5 pence each in
financial instrument, Diurnal Group plc
type of instrument
Identification code GB00BDB6Q760
b) Nature of the transaction Sale and purchase of ordinary shares
----------------------------- ---------------------------------------------
c) Price(s) and volume(s)
--------------------- ----------
Price(s) Volume(s)
--------------------- ----------
Sale 66.5p 22,000
Purchase 66.55p 22,000
-------------------------------------------------------------- ----------
d) Aggregated information
- Aggregated volume As above
- Price
e) Date of the transaction 12 May 2021
----------------------------- ---------------------------------------------
f) Place of the transaction XLON
----------------------------- ---------------------------------------------
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Sarah Ross
------------------------------ --------------------------------------------------
2 Reason for the notification
----------------------------------------------------------------------------------
a) Position/status Closely associated person to an Executive
Director
------------------------------ --------------------------------------------------
b) Initial notification Initial notification
/Amendment
------------------------------ --------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
----------------------------------------------------------------------------------
a) Name Diurnal Group plc
------------------------------ --------------------------------------------------
b) LEI 213800I2HNUNZN1LDH29
------------------------------ --------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
----------------------------------------------------------------------------------
a) Description of the Ordinary shares of 5 pence each in
financial instrument, Diurnal Group plc
type of instrument
Identification code GB00BDB6Q760
b) Nature of the transaction Sale and purchase of ordinary shares
------------------------------ --------------------------------------------------
c) Price(s) and volume(s)
------------------------ -------------
Price(s) Volume(s)
------------------------ -------------
Sale 66.5p 20,000
Purchase 66.55p 20,000
------------------------------------------------------------------ -------------
d) Aggregated information
- Aggregated volume As above
- Price
e) Date of the transaction 12 May 2021
------------------------------ --------------------------------------------------
f) Place of the transaction XLON
------------------------------ --------------------------------------------------
For further information, please visit www.diurnal.co.uk or
contact:
+44 (0)20 3727
Diurnal Group plc 1000
Martin Whitaker, Chief Executive Officer
Richard Bungay, Chief Financial Officer
Panmure Gordon (UK) Limited (Nominated Adviser +44 (0)20 7886
and Sole Broker) 2500
Corporate Finance: Freddy Crossley, Emma Earl
Corporate Broking: Rupert Dearden
+44 (0)20 3727
FTI Consulting (Media and Investor Relations) 1000
Simon Conway
Victoria Foster Mitchell
Alex Davis
Notes to Editors
About Diurnal Group plc
Diurnal Group plc is a European, UK-headquartered, specialty
pharmaceutical company dedicated to developing hormone therapeutics
to aid lifelong treatment for rare and chronic endocrine
conditions, including congenital adrenal hyperplasia, adrenal
insufficiency, hypogonadism and hypothyroidism. Its expertise and
innovative research activities focus on circadian-based
endocrinology to yield novel product candidates in the rare and
chronic endocrine disease arena.
For further information about Diurnal, please visit
www.diurnal.co.uk
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHFLFVRELIFLIL
(END) Dow Jones Newswires
May 12, 2021 12:32 ET (16:32 GMT)
Diurnal (LSE:DNL)
Historical Stock Chart
From Apr 2024 to May 2024
Diurnal (LSE:DNL)
Historical Stock Chart
From May 2023 to May 2024